Linike Medical Group Ltd (LNMG) Fair Value & Analysis
Healthcare · US · Market cap $3.3M
Linike Medical Group Ltd
LNMG · US
Fair value as of: Aug 13, 2026
From 7 valuation models · updated 4 days ago
Fair value updated Aug 13, 2026, revised from $0.0065 to $0.0049 (−24.5%) since Jul 31, 2026. Share price −22.1% over the past month.
Below-average quality, currently priced close to our fair value.
What matters now
- The price sits above even our optimistic bull case ($0.0050). The favourable scenario is already priced in.
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- The models converge in a tight band ($0.0049 to $0.0050), unusually little disagreement for a valuation.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range $0.0028 – $4.73 · fair‑value band $0.0049 – $0.0050 · the $0.0053 price screens above the $0.0049 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Linike Medical Group Ltd (LNMG) currently trades at $0.0053, while our model-based Fair Value estimate is $0.0049, implying the stock looks roughly 7.6% fairly valued today. The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Net debt stands at $16.9M. Fundamentals as of Aug 13, 2026
Our scenario range runs from $0.0049 (bear case) to $0.0050 (bull case); at $0.0053, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at -33% fair-value upside, at -8%, LNMG screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 7 models by family
Widest divergence: Earnings-Based ($0.1600) versus Asset-Based ($0.0400). Highest evidence: P/E Multiple (63).
Notify me when LNMG reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Quality Score breakdown
Of which business quality 50 · Market factors (momentum, volatility) 16
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Linike Medical Group Ltd. engages in the renewable energy business. The company is involved in the creation of a solar farm in India. It also focuses on commercial real estate development business. The company was formerly known as Litian Group Inc. and changed its name to Linike Medical Group Ltd. in August 2021. Linike Medical Group Ltd.
Full company description
Linike Medical Group Ltd. engages in the renewable energy business. The company is involved in the creation of a solar farm in India. It also focuses on commercial real estate development business. The company was formerly known as Litian Group Inc. and changed its name to Linike Medical Group Ltd. in August 2021. Linike Medical Group Ltd. is based in Calgary, Canada.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2012 – FY2025 · reported fiscal years
Linike Medical Group Ltd reported revenue of $10.7M in FY2025 versus $69.3K in FY2012, a compound +47.3%/yr. Reported net income was $3.1M in FY2025.
Watch LNMG: get an alert when its fair value changes →
Peer Group
Medical Devices · 353 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 30/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $110.91 | $74.79 | -33% |
| Stryker Corporation SYK | $347.21 | $186.28 | -46% |
| Medtronic plc MDT | $90.76 | $65.57 | -28% |
| Boston Scientific Corporation BSX | $51.42 | $38.44 | -25% |
| Edwards Lifesciences Corporation EW | $93.05 | $41.02 | -56% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥153.60 | ¥147.63 | -4% |
| Shanghai United Imaging Healthcare Co 688271 | ¥110.50 | ¥43.60 | -61% |
| Demant A/S DEMANT | kr 289.60 | kr 161.17 | -44% |
| Getinge AB GETIB | kr 239.30 | kr 192.14 | -20% |
| Sectra AB SECTB | kr 280.00 | kr 66.81 | -76% |
Compare Linike Medical Group Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Linike Medical Group Ltd (LNMG) overvalued or undervalued?
What is the fair value of LNMG?
What is the quality score of LNMG?
What is the net profit margin of LNMG?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Linike Medical Group Ltd and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.